ORYZON Announces New Grant from Alzheimer's Drug Discovery Foundation (ADDF) to develop a companion marker for its ORY-2001 ...
BARCELONA, SPAIN and CAMBRIDGE, MA--(Marketwired - April 24, 2017) - Oryzon Genomics (ISIN Code: ES0167733015) (MAD: ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical …